Semaglutide, tirzepatide, and other glucagon-like peptide-1 (GLP-1) receptor agonists have become some of the most discussed medications of recent years. The longer people take these drugs, the more data accumulates regarding adverse reactions. In November 2026, the US Food and Drug Administration (FDA), following the European Medicines Agency and the World Health Organization, issued a warning: in rare cases, taking these medications can lead to irreversible vision loss in one eye.
How GLP-1 receptor agonists work
Glucagon-like peptide-1 is produced in the brain and gut after a person starts eating. It binds to receptors in various organs: insulin production is stimulated, hunger is suppressed, food stays in the stomach longer, and satiety is reached faster. Nausea is frequently a side effect, which additionally reduces appetite. As a result, a person eats less and loses weight. GLP-1 receptor agonists are drugs that bind to the same receptors and reproduce a similar effect. Originally intended for treating type 2 diabetes and clinical obesity, they are now increasingly used by people without strict medical indications amid sustained demand and the trend for rapid figure correction.
What the FDA specifically warned about
The mechanism of damage is linked to the cessation of blood flow to the optic nerve. As a result, vision sharply deteriorates, and in rare cases, is lost entirely. This condition is called non-arteritic anterior ischemic optic neuropathy. The exact causes of its development are unknown, but the risk is higher in people with a number of comorbid conditions. The FDA analyzed accumulated data and calculated that per year, out of 100,000 people using GLP-1 receptor agonists, the optic nerve is damaged 6.4 times, whereas in those not taking these medications (placebo or other drugs), it is 3.8 times.
Why it is difficult to assess the real frequency
People for whom such medications are prescribed often already have the listed risk factors, making it hard to understand whether GLP-1 agonists contribute an independent effect. Moreover, the condition is rare: in the US, approximately 1 in 200,000 people, and among those over 50, about 5 to 20 per 200,000. Due to such low frequency, clinical trial scales are usually insufficient to capture the problem and draw reliable conclusions. Some adverse reactions have already been added to drug labeling—specifically in the European Union, the UK, and/or the US.
Signs and what to do if they appear
If you are taking GLP-1 receptor agonists, you may want to reconsider this decision with your doctor. If you consider the risks acceptable, it is important to remember the signs of non-arteritic anterior ischemic optic neuropathy and urgently consult an ophthalmologist: sudden, usually painless loss of vision in one eye; in rare cases, headache, eye pain, or discomfort. There is no treatment that would stop the process or restore vision, but it is important to get a correct diagnosis (perhaps the cause is something else that can be managed) and take measures that will likely reduce the risk for the second eye: discontinuing the drug, controlling blood pressure and glucose levels. There is currently no certainty that this helps, but maintaining normal parameters is useful in any case.
Myths about hair loss and "Ozempic face"
The media and social networks have talked a lot about GLP-1 agonists causing hair loss and facial skin sagging ("Ozempic face"). According to researchers, this information was based on less-than-reliable studies. Hair does likely fall out, but this is related not so much to the drugs as to the stress on the body during weight loss—the same thing happens after stomach reduction surgery, and hair density usually recovers. Vitamin and mineral deficiencies from poor nutrition may also play a role, making a balanced diet important. "Ozempic face" is also mainly a consequence of rapid weight loss; the drugs themselves may contribute somewhat, but not primarily.